Advanced search
Publication Cover
Leukemia & Lymphoma Volume 51, 2010 - Issue 12
Submit an article Journal homepage
220
Views
21
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia

Tait ShanafeltDepartment of Medicine, Mayo Clinic, Rochester, MN, USACorrespondence[email protected]
,
Clive ZentDepartment of Medicine, Mayo Clinic, Rochester, MN, USA
,
John ByrdDepartment of Medicine, Ohio State University, Columbus, OH, USA
,
Charles ErlichmanDepartment of Oncology, Mayo Clinic, Rochester, MN, USA
,
Betsy LaplantDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
,
Asish GhoshDepartment of Medicine, Mayo Clinic, Rochester, MN, USA
,
Timothy CallDepartment of Medicine, Mayo Clinic, Rochester, MN, USA
,
Miguel Villalona-CaleroDepartment of Medicine, Ohio State University, Columbus, OH, USA
,
Diane JelinekDepartment of Immunology, Mayo Clinic, Rochester, MN, USA
,
Deborah BowenDepartment of Medicine, Mayo Clinic, Rochester, MN, USA
,
Kristina LaumannDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
,
Wenting WuDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
,
Curtis HansonDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
&
Neil KayDepartment of Medicine, Mayo Clinic, Rochester, MN, USA
 show all
Pages 2222-2229 | Received 14 Jul 2010, Accepted 13 Sep 2010, Published online: 05 Nov 2010

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Tomohiro Funakoshi & Yuichi J. Shimada. (2013) Risk of hypothyroidism in patients with cancer treated with sunitinib: A systematic review and meta-analysis. Acta Oncologica 52:4, pages 691-702.
Read now
Rena Buckstein, John Kuruvilla, Neil Chua, Christina Lee, David A. Macdonald, Abdulwahab J. Al-tourah, Alison H. Foo, Wendy Walsh, S. Percy ivy, Michael Crump & Elizabeth A. Eisenhauer. (2011) Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group. Leukemia & Lymphoma 52:5, pages 833-841.
Read now

Articles from other publishers (19)

Lei Jiang & Nailin Li. (2020) B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy. Angiogenesis 23:4, pages 515-529.
Crossref
Carlos Cuesta-Mateos, Ana Alcaraz-Serna, Beatriz Somovilla-Crespo & Cecilia Muñoz-Calleja. (2018) Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets. Frontiers in Immunology 8.
Crossref
Neil E. Kay, Paolo Strati, Betsy R. LaPlant, Jose F. Leis, Daniel Nikcevich, Timothy G. Call, Adam M. Pettinger, Connie E. Lesnick, Curtis A. Hanson & Tait D. Shanafelt. (2016) A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia. Oncotarget 7:48, pages 78269-78280.
Crossref
Sina OppermannJarkko YlankoYonghong ShiSantosh HariharanChristopher C. OakesPatrick M. BrauerJuan C. Zúñiga-PflückerBrian LeberDavid E. Spaner & David W. Andrews. (2016) High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. Blood 128:7, pages 934-947.
Crossref
Andreas K.A. Gaumann, Friedemann Kiefer, Joachim Alfer, Sven A. Lang, Edward K. Geissler & Georg Breier. (2016) Receptor tyrosine kinase inhibitors: Are they real tumor killers?. International Journal of Cancer 138:3, pages 540-554.
Crossref
Ranjan Upadhyay, Linda Hammerich, Paul Peng, Brian Brown, Miriam Merad & Joshua Brody. (2015) Lymphoma: Immune Evasion Strategies. Cancers 7:2, pages 736-762.
Crossref
Nadine KutschReinhard MarksRichard RateiThomas K. HeldMartin Schmidt-Hieber. (2015) Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms. Biomarker Insights 10s3, pages BMI.S22434.
Crossref
Kyle Crassini. (2015) Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date. World Journal of Clinical Cases 3:8, pages 694.
Crossref
Preetesh Jain, Hun Ju Lee, Wei Qiao, William Wierda, Ohad Benjamini, Jan Burger, Alessandra Ferrajoli, Zeev Estrov, Hagop Kantarjian, Michael Keating & Susan O'Brien. (2014) FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer 120:22, pages 3494-3501.
Crossref
Carol Lozano-Santos, Jimena Martinez-Velasquez, Belen Fernandez-Cuevas, Natividad Polo, Belen Navarro, Isabel Millan, Jose Miguel Garcia, Rosa Collado, Pedro Sanchez-Godoy, Felix Carbonell, Jose Antonio Garcia-Vela, Jose Antonio Garcia-Marco & Natalia Gomez-Lozano. (2014) Vascular Endothelial Growth Factor A (VEGFA) Gene Polymorphisms Have an Impact on Survival in a Subgroup of Indolent Patients with Chronic Lymphocytic Leukemia. PLoS ONE 9:6, pages e101063.
Crossref
Tomohiro Funakoshi, Asma Latif & Matthew D. Galsky. (2013) Risk of hematologic toxicities in cancer patients treated with sunitinib: A systematic review and meta-analysis. Cancer Treatment Reviews 39:7, pages 818-830.
Crossref
Domenico Ribatti. (2013) Angiogenesis as a treatment target in leukemia. International Journal of Hematologic Oncology 2:3, pages 229-242.
Crossref
Donatella Marino, Francesco Leone, Giuliana Cavalloni, Celeste Cagnazzo & Massimo Aglietta. (2013) Biliary tract carcinomas: From chemotherapy to targeted therapy. Critical Reviews in Oncology/Hematology 85:2, pages 136-148.
Crossref
Asish K. Ghosh & Neil E. Kay. 2013. Advances in Chronic Lymphocytic Leukemia. Advances in Chronic Lymphocytic Leukemia 215 239 .
Julian Paesler, Iris Gehrke, Simon Jonas Poll-Wolbeck & Karl-Anton Kreuzer. (2012) Targeting the vascular endothelial growth factor in hematologic malignancies. European Journal of Haematology 89:5, pages 373-384.
Crossref
Yi Xia, Rui-Nan Lu & Jianyong Li. (2012) Angiogenic factors in chronic lymphocytic leukemia. Leukemia Research 36:10, pages 1211-1217.
Crossref
Abdo J. Najy, Young Suk Jung, Joshua J. Won, M. Katie Conley-LaComb, Allen Saliganan, Chong Jai Kim, Elisabeth Heath, Michael L. Cher, R. Daniel Bonfil & Hyeong-Reh Choi Kim. (2012) Cediranib inhibits both the intraosseous growth of PDGF D-Positive prostate cancer cells and the associated bone reaction. The Prostate 72:12, pages 1328-1338.
Crossref
Ana Markovic, Karen L. MacKenzie & Richard B. Lock. (2012) Induction of Vascular Endothelial Growth Factor Secretion by Childhood Acute Lymphoblastic Leukemia Cells via the FLT-3 Signaling Pathway. Molecular Cancer Therapeutics 11:1, pages 183-193.
Crossref
Shuo Ma & Steven T. Rosen. (2011) Signal transduction inhibitors in chronic lymphocytic leukemia. Current Opinion in Oncology 23:6, pages 601-608.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.